What is the price target for UTHR stock?
21 analysts have analysed UTHR and the average price target is 546.8 USD. This implies a price increase of 2.82% is expected in the next year compared to the current price of 531.82.
NASDAQ:UTHR • US91307C1027
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for UNITED THERAPEUTICS CORP (UTHR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-23 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-03-12 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-03-05 | UBS | Maintains | Buy -> Buy |
| 2026-02-26 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-26 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-02-26 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-26 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-06 | UBS | Maintains | Buy -> Buy |
| 2025-11-06 | UBS | Maintains | Buy -> Buy |
| 2025-10-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-30 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-29 | UBS | Maintains | Buy -> Buy |
| 2025-09-26 | RBC Capital | Initiate | Outperform |
| 2025-09-10 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-09-05 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-04 | UBS | Maintains | Buy -> Buy |
| 2025-09-03 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-02 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-09-02 | Jefferies | Maintains | Buy -> Buy |
| 2025-08-13 | UBS | Maintains | Buy -> Buy |
| 2025-07-31 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.328B 20.20% | 2.877B 23.63% | 3.183B 10.61% | 3.407B 7.05% | 3.86B 13.30% | 4.394B 13.83% | 5.069B 15.36% | 5.657B 11.60% | 6.505B 14.99% | 6.848B 5.27% | 7.253B 5.91% | |
| EBITDA YoY % growth | 1.242B 19.14% | 1.521B 22.46% | 1.603B 5.41% | 1.758B 9.68% | 1.894B 7.74% | 2.066B 9.08% | 1.131B -45.26% | 1.079B -4.60% | 1.044B -3.24% | N/A | N/A | |
| EBIT YoY % growth | 1.189B 19.94% | 1.448B 21.84% | 1.517B 4.77% | 1.617B 6.58% | 1.888B 16.76% | 2.171B 14.99% | 2.545B 17.23% | 2.888B 13.48% | 3.671B 27.11% | 3.135B -14.60% | 3.243B 3.44% | |
| Operating Margin | 51.06% | 50.33% | 47.67% | 47.46% | 48.91% | 49.41% | 50.21% | 51.05% | 56.43% | 45.78% | 44.71% | |
| EPS YoY % growth | 19.84 32.09% | 24.60 23.99% | 27.90 13.41% | 29.87 7.05% | 33.42 11.88% | 36.86 10.32% | 43.38 17.68% | 46.95 8.22% | 58.59 24.79% | 53.93 -7.95% | 55.28 2.51% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 7.09 6.93% | 7.37 14.98% | 7.62 6.39% | 8.01 3.96% |
| Revenue Q2Q % growth | 825.73M 3.94% | 846.7M 6.02% | 889.09M 11.21% | 910.63M 15.24% |
| EBITDA Q2Q % growth | 427.37M 6.15% | 447.21M 4.71% | 447.82M -0.95% | 452.79M 2.19% |
| EBIT Q2Q % growth | 355.84M -7.04% | 367.08M -4.95% | 432.98M 11.22% | 431.44M 20.68% |
All data in USD
21 analysts have analysed UTHR and the average price target is 546.8 USD. This implies a price increase of 2.82% is expected in the next year compared to the current price of 531.82.
UNITED THERAPEUTICS CORP (UTHR) will report earnings on 2026-04-28, before the market open.
The consensus EPS estimate for the next earnings of UNITED THERAPEUTICS CORP (UTHR) is 7.09 USD and the consensus revenue estimate is 825.73M USD.
The expected long term growth rate for UNITED THERAPEUTICS CORP (UTHR) is 10.39%.